HROC348 Cells
USUSD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | HROC348 is a human colorectal carcinoma cell line derived from a primary tumor resected from an adult male patient diagnosed with sigmoid colon cancer. The tumor was classified as a moderately advanced adenocarcinoma (T3, G3, N2), indicating significant local invasion and lymph node involvement, consistent with aggressive tumor behavior. The carcinoma originated in the sigmoid colon, a common anatomical site for sporadic colorectal cancer, and presented with microsatellite stability (MSS), which aligns it with the chromosomal instability (CIN) subtype rather than the MSI-high hypermutated class of colorectal tumors. Molecular profiling of HROC348 shows wild-type status for both KRAS and BRAF, suggesting the absence of common activating mutations in these genes that are frequently implicated in colorectal cancer progression and therapy resistance. This molecular background makes HROC348 particularly suitable for studies focused on non-mutated RAS/RAF signaling and its implications in tumor growth, therapeutic response, and resistance mechanisms. The cell line does not display the CpG island methylator phenotype (CIMP), further supporting its classification within the conventional (non-hypermutated) colorectal cancer subgroup. Clinically, the tumor was positive for lymph node metastasis (LN_pos = 2), but distant metastasis (M) was noted only once, and no right-sided colon involvement was recorded, consistent with a left-sided colorectal cancer profile. These features, combined with the MSS status and molecular markers, position HROC348 as a representative model for studying left-sided, KRAS/BRAF wild-type, microsatellite-stable colorectal adenocarcinoma. It also offers translational value for preclinical testing of targeted therapies and immune-modulatory agents in MSS tumors, which are typically less responsive to immune checkpoint blockade. |
|---|---|
| 生物體 | Human |
| 組織 | Sigmoid colon |
| 疾病 | Carcinoma |
| 轉移部位 | Not reported (primary sigmoid colon adenocarcinoma; no confirmed distant metastasis at time of sampling) |
| 應用 | Colorectal cancer research; KRAS/BRAF wild-type MSS CRC biology; left-sided colorectal cancer modeling; drug sensitivity in non-mutated RAS/RAF tumors; HROC Linnebacher biobank studies; CRC immunotherapy evaluation; preclinical oncology |
特徵
| 年齡 | 77 years |
|---|---|
| 性別 | Male |
| 族裔 | Caucasian |
| 形態學 | Epithelial-like |
| 細胞類型 | Epithelial cells |
| 生長特性 | Adherent |
監管數據
| 引用 | HROC348 (Cytion catalog number 300719) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | Not assigned |
| 轉基因狀態 | No genetic modification; wildtype patient-derived CRC cell line from the HROC Linnebacher biobank. KRAS wild-type, BRAF wild-type, MSS, CIMP-negative. |
生物分子資料
| MSI 狀態 | MSS |
|---|
處理方式
| 培養基 | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS |
| 解離試劑 | Accutase |
| 傳代培養 | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| 流體更新 | 2 to 3 times per week |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
分析證明書 (CoA)
| 批次編號 | 證書類型 | 日期 | 型號 |
|---|---|---|---|
| 300719-280325 | 分析證明書 | 23. May. 2025 | 300719 |